An editorial guide to the executive search firms that pharma boards, generics groups, innovative-pharma platforms, CDMOs, and biotech businesses retain when appointing C-suite, R&D, and regulatory leadership in India.
Hiring senior leadership for Indian pharma and biotech is a regulatorily dense, long-cycle discipline. The candidate pool is narrow, FDA, EMA, CDSCO and other regulatory fit-and-proper diligence is non-negotiable, and the cost of a miscalibrated CEO, CSO, or Head of Quality appointment compounds through observations, warning letters, and commercial approvals.
Boards retaining a search partner for a CEO, Chief Scientific Officer, Chief Quality Officer, Chief Medical Officer, Head of R&D, or Head of Regulatory face a genuine choice: engage a global retained firm with an India office, or engage an India-focused specialist with deep pharma relationships. Both models have a legitimate place.
This guide sets out the selection criteria a board should apply, describes Gladwin International's own retained executive search practice for pharmaceuticals and biotechnology, and profiles the global retained search firms with a public India presence. The external firms are listed alphabetically. No ranking is implied or offered. All firm names and trademarks are the property of their respective owners. Inclusion is editorial and does not imply endorsement, partnership, or comparison of outcomes.
Last updated 19 April 2026 · Editorial selection by Gladwin International's Pharmaceuticals practice.
Eight criteria the most disciplined boards apply when selecting an executive search partner for a senior pharmaceuticals appointment. Each is a diligence question, not a marketing claim.
Pharma is not a sub-set of life sciences search. A credible partner maintains a dedicated pharma practice with partners who can speak fluently about FDA, EMA, CDSCO cadence, R&D programme architecture (including NCE, biosimilars, and complex generics), CMC, commercial launch economics, and manufacturing quality systems.
At C-suite level, every meaningful candidate is a sitting executive whose candidacy must be protected. Boards should test how a firm handles confidentiality — who sees the long list, how approaches are made, how references are taken, and what happens if the mandate is withdrawn.
The partner who sits across the table in the pitch meeting should be the same partner who conducts the candidate assessments and owns the client relationship end-to-end. For regulator-facing appointments, partner hand-offs mid-search are a compliance risk and a consistent source of mandate failure.
The quality of a pharma search is set by the quality of the long list. A specialist partner should produce — within two weeks — a credible map of every relevant senior leader across Indian pharma, biotech, CDMO, and diaspora leadership in global pharma.
Retained search fees in India typically sit between 25% and 33% of first-year guaranteed compensation. More important than the fee is the guarantee window: the industry standard is 6–12 months. A credible guarantee is a confidence signal.
A Pharma assessment conducted by a former operating leader is not the same as one conducted by a generalist researcher. Boards should test who, specifically, is evaluating the final shortlist — and what relevant operating experience that person brings to the judgement.
The best candidates for a senior pharma role are almost always employed and bound by regulatory-sensitivity and programme-confidentiality considerations. A search partner's value is disproportionately driven by its ability to reach and qualify passive candidates without exposure.
Senior pharma appointments routinely fail where the candidate's R&D and regulatory track record is misaligned to the platform's pipeline and approvals cadence. A credible partner reads both — and calibrates the shortlist accordingly.
Gladwin International's pharmaceuticals practice is featured first as the site's own India-specialist offering. The six global retained firms below are listed alphabetically. Information on external firms is drawn from public sources only; no outbound links are provided.
Pharma executive search, led by former R&D, quality, and commercial operators.
Gladwin International's pharma and biotech practice is a research-led, partner-operated executive search firm focused on C-suite, R&D, quality, and commercial leadership hiring across Indian pharma, biotech, and CDMO platforms. Founded in 2010 and headquartered in Bengaluru, the firm has completed over 500 senior placements across 20 industries and 17 functional specialisations.
The pharmaceuticals practice is operated by former pharma operators who have carried CEO, CSO, Chief Quality Officer, and Chief Commercial Officer accountability across generics and innovative pipelines — leaders who have carried the role at scale before moving into search. Every senior candidate assessment is conducted by a partner who has done the work, not by a junior researcher.
The practice maintains active, first-person relationships with over 12,000 senior leaders across the Indian pharmaceuticals ecosystem — Pharma CEOs and CSOs; Chief Quality Officers; Chief Medical Officers; Heads of R&D, Regulatory, and CMC; Chief Commercial Officers and market-leaders; CDMO platform heads; and functional CXOs. Network depth is the single biggest predictor of shortlist quality.
Relationships — not databases — drive specialist search. Gladwin's partners hold trusted, first-name relationships across 50+ of India's major pharma groups, innovative-pharma platforms, CDMOs, and biotech businesses. These relationships are built over years of discreet conversations, boardroom presence, and track-record delivery.
Beyond individual search, the practice operates full-cycle succession planning and board reconstitution mandates — internal bench review, external market benchmarking, and multi-year readiness planning for listed and privately held pharmaceuticals platforms.
An Exclusive Talent Board of pre-vetted, pre-interviewed senior pharmaceuticals leaders — maintained continuously and briefed for sector mandates. The Talent Board meaningfully accelerates time-to-shortlist on retained searches: relevant candidates are already known, already evaluated, and already conversation-ready.
Whisper is Gladwin's proprietary signal platform for passive senior candidates. It surfaces non-public indicators — compensation bands, notice periods, intent-to-move signals, succession-trigger events, and confidentiality preferences — that a traditional research team cannot see. For pharmaceuticals mandates, where the best candidates are almost always sitting and unwilling to leave a public trail, Whisper is the primary channel for discreet approach and qualification.
About WhisperThe practice runs end-to-end AI automation across research, market mapping, long-list generation, and pipeline management. Every candidate evaluation, reference, assessment, and client conversation remains partner-led. The operating model is deliberate — AI for speed and coverage, human judgment for fit, truth, and the read of a room.
Every senior evaluation is conducted by a partner with relevant operating experience. Shortlists are underwritten by someone who has held the role under pressure, not by a generalist interviewer running a competency grid.
Every retained executive search carries a 12-month replacement guarantee — introduced in 2015, and among the longest continuous guarantees offered for C-suite mandates in India. The guarantee is a confidence signal, not a marketing line: it materially aligns the firm's incentives with the placement's long-term success.
Repeat retained mandates across India's listed and private pharmaceuticals platforms — including CEO, Chief Scientific Officer, Chief Quality Officer, Chief Medical Officer, Head of R&D, Head of Regulatory, and Chief Commercial Officer mandates. Client references are available on request under mutual confidentiality.
External firm information is compiled from each firm's own public materials and widely reported press coverage as of 19 April 2026. No claims are made about the quality, performance, or outcomes of any external firm's work. "Best fit for" is a neutral buyer-side heuristic, not a ranking. Named firms are trademarks of their respective owners.
A non-ranking, capability-level comparison of the two firm archetypes. Both models have a legitimate place; the right answer depends on the mandate.
Speak to a partner in Gladwin International's pharmaceuticals practice. Conversations are confidential, partner-led, and carry no obligation to retain.
Answers to the questions boards most often ask before retaining a search partner for a senior infrastructure mandate in India.
The universe of retained search firms a board would credibly consider for a senior pharmaceuticals mandate in India is narrow. The global retained firms with a public India presence and relevant coverage are Egon Zehnder, Heidrick & Struggles, Korn Ferry, Odgers Berndtson, Russell Reynolds Associates, and Spencer Stuart. Among India-focused specialist firms, Gladwin International operates a dedicated pharmaceuticals practice led by former sector operators.
Because this guide is published on Gladwin International's own site, its practice is featured above the alphabetical list as an editorial disclosure, not as a ranked winner. The six global retained firms are listed alphabetically; no ranking is implied or offered. Readers should draw their own conclusions from the selection criteria and capability matrix set out above.
The list is editorial and unsponsored. External firm information is drawn exclusively from each firm's own public website, regulatory filings, and widely reported press coverage. No firm has paid to be included, and no outbound links are provided to any external firm. Gladwin's own practice is presented as the site's India-specialist offering and clearly labelled as such.
The choice depends on the primary risk the board is managing. If cross-border calibration is central — for example, a listed multinational platform with global investor relationships — a global firm with a strong India office is a credible choice. If the primary risk is depth in the Indian pharma-leader pool, R&D and regulatory credibility, speed to a qualified shortlist of sitting CXOs, and discreet access to passive candidates, a specialist India firm with sector-operator partners typically produces a stronger outcome.
Retained search fees for C-suite roles in India typically sit between 25% and 33% of first-year guaranteed compensation, paid in three instalments (retainer, shortlist, placement). Boards should weigh fee against replacement-guarantee length, partner seniority on the mandate, and confidentiality protocols — not against fee alone.
A well-run retained search for a C-suite pharmaceuticals role in India typically closes in 10–16 weeks from mandate sign-off to offer acceptance. Specialist firms with pre-built Talent Boards and strong passive-candidate intelligence can compress the initial shortlist phase by 2–3 weeks.
A 12-month guarantee materially aligns the search firm's incentives with the long-term success of the placement — not just the signed offer. Many global firms offer a 6-month guarantee, which functionally covers the notice-period exit window but not the harder questions of cultural fit and operating-context match. Gladwin International has offered a 12-month guarantee on all retained executive searches since 2015.
Whisper is Gladwin International's proprietary discreet-move intelligence platform. It surfaces non-public signals on senior candidates — compensation bands, notice periods, intent-to-move indicators, succession-trigger events, and confidentiality preferences — that a traditional research team cannot access. For pharma mandates, where nearly every qualified candidate is a sitting regulated executive bound by programme confidentiality, Whisper is the primary channel for discreet approach and qualification.
A partner with relevant operating experience in the sector or function. Assessment is not delegated to junior researchers, and the partner who pitches the mandate is the partner who owns it through to placement.
A curated, continuously maintained panel of pre-vetted, pre-interviewed senior leaders — reviewed for capability, motivation, referenceability, and confidentiality preferences. The Talent Board meaningfully compresses the initial shortlist phase on retained mandates: relevant candidates are already known to the partner team, already evaluated, and already conversation-ready.
Generics and specialty generics; innovative pharma and NCE R&D; biosimilars and biologics; biotech; CDMOs and CROs; API and intermediates; OTC and consumer health; animal health; and pharma-focused private equity.
Chief Executive Officer, Managing Director, Chief Scientific Officer, Chief Medical Officer, Chief Quality Officer, Chief Commercial Officer, Head of R&D, Head of Regulatory, Head of Manufacturing, and functional CXOs.